Rigel Pharmaceuticals Inc., often written as RIGL, is a biomedical company based in South San Francisco, California. Founded in 1996, Rigel Pharmaceuticals has spent over two decades focusing on creating new and innovative drugs for the treatment of immune and hematological disorders, cancers, and rare diseases. The company's determination to develop and introduce high-quality medicines for chronic and serious medical conditions has made it a reputable player in the medical and biotechnology industry.
Rigel Pharmaceuticals operates under dynamic leadership, aiming to impact global healthcare through the discovery and development of innovative, breakthrough drugs. A flagship product for Rigel, developed in-house, is Tavalisse (Fostamatinib). This drug is approved in the US for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
The company's expertise is put into practice through the phases of drug discovery, preclinical testing, clinical trials, and market release. While progressing through numerous steps from laboratory to market, Rigel maintains a high standard of operations to ensure the safety and efficacy of its products. Moreover, the company prides itself on a robust pipeline of drugs under development to address unmet medical needs.
Rigel Pharmaceuticals is not only committed to scientific advancement but also to its employees, placing a high emphasis on maintaining an inclusive, collaborative, and innovative work environment. With a culture that promotes empowerment and teamwork, the company continually invests in employee development and believes that every team member contributes to its overall success.
Rigel has a strong, long-standing commitment to corporate responsibility and ethical business practices. The company also actively engages in community outreach and philanthropic initiatives, emphasizing the importance of making a positive societal impact.
In conclusion, Rigel Pharmaceuticals Inc. occupies a unique position within the biopharmaceutical industry, leveraging its deep knowledge in drug discovery to tackle challenging diseases. Its mission, to deliver transformative treatments to patients and significantly improve their lives, continues to drive the company's commitment to research and development. This commitment propels Rigel's enduring efforts to bring innovative and effective solutions to market, thereby exceeding expectations of patients, care providers, and investors. As Rigel continues its molecular trailblazing, the company ushers in a new era of possibilities in drug discovery and development.